Grafa News and Videos — Page 259

Peoples Bancorp of North Carolina (NASDAQ:PEBK) reported second-quarter 2026 net earnings of $5.2 million, or $0.98 per basic share and $0.96 per diluted share.

U.S. stock futures climbed Monday as oil prices declined after Iran signaled it remained open to negotiations following nine days of U.S. strikes.

AMC Entertainment Holdings (NYSE:AMC) reported second-quarter revenue of $1.5967 billion, an increase of 14.2% from $1.3979 billion a year earlier.

MainStreet Bancshares (NASDAQ:MNSB) reported second-quarter 2026 net income of $4.7 million, driven by disciplined expense management and steady loan growth.

Destination XL Group (NASDAQ:DXLG) filed a preliminary proxy statement with the SEC regarding its pending merger agreement with FBB Holdings I, also known as FullBeauty.

Dynex Capital (NYSE:DX) reported second-quarter economic return of $0.81 per common share and book value of $12.90 per share as of June 30, 2026.

Halozyme Therapeutics (NASDAQ:HALO) announced a global collaboration and license agreement with Incyte (NASDAQ:INCY) to develop subcutaneous formulations of INCA033989.

Nuvation Bio (NYSE:NUVB) reported updated long-term Phase 2 data for safusidenib in chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant glioma.

VERAXA Biotech (NASDAQ:VRXA) received Scientific Advice from Germany’s Paul-Ehrlich-Institute on the biological rationale and non-clinical development plan for its lead BiTAC-TCE programme.

Dyne Therapeutics (NASDAQ:DYN) received FDA acceptance of its Biologics License Application for z-rostudirsen, an investigational treatment for Duchenne muscular dystrophy amenable to exon 51 skipping.